{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T21:32:05Z","timestamp":1788039125803,"version":"build-2784847793"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["2017R1A2B4012636"],"award-info":[{"award-number":["2017R1A2B4012636"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003710","name":"Korean Health Industry Development Institute","doi-asserted-by":"crossref","award":["HI14C3331"],"award-info":[{"award-number":["HI14C3331"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Recently, several studies suggested potential involvements of \u03b1-synuclein in Alzheimer\u2019s disease (AD) pathophysiology. Higher concentrations of \u03b1-synuclein were reported in cerebrospinal fluid (CSF) of AD patients with a positive correlation towards CSF tau, indicating its possible role in AD. We analyzed the CSF biomarkers to verify whether \u03b1-synuclein could be an additional supported biomarker in AD diagnosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this cross-sectional study, CSF samples of 71 early-onset AD, 34 late-onset AD, 11 mild cognitive impairment, 17 subjective cognitive decline, 45 Parkinson\u2019s disease, and 32 healthy control (HC) were collected. CSF amyloid-\u03b21-42 (A), total tau (N), and phosphorylated tau181 (T) were measured by commercial ELISA kits, and in-house ELISA kit was developed to quantify \u03b1-synuclein. The cognitive assessments and amyloid-PET imaging were also performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>CSF \u03b1-synuclein manifested a tendency to increase in AD and to decreased in Parkinson\u2019s disease compared to HC. The equilibrium states of total tau and \u03b1-synuclein concentrations were changed significantly in AD, and the ratio of total tau\/\u03b1-synuclein (N\/\u03b1S) was dramatically increased in AD than HC. Remarkably, N\/\u03b1S revealed a strong positive correlation with tau phosphorylation rate. Also, the combination of N\/\u03b1S with amyloid-\u03b21-42\/phosphorylated tau181\u00a0ratio had the best diagnosis performance (AUC\u2009=\u20090.956, sensitivity\u2009=\u200996%, specificity\u2009=\u200987%). In concordance analysis, N\/\u03b1S showed the higher diagnostic agreement with amyloid-\u03b21-42 and amyloid-PET. Analysis of biomarker profiling with N\/\u03b1S had distinctive characteristics and clustering of each group. Especially, among the group of suspected non-Alzheimer\u2019s disease pathophysiology, all A\u2212T+N+ patients with N\/\u03b1S+ were reintegrated into AD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The high correlation of \u03b1-synuclein with tau and the elevated N\/\u03b1S in AD supported the involvement of \u03b1-synuclein in AD pathophysiology. Importantly, N\/\u03b1S improved the diagnostic performance, confirming the needs of incorporating \u03b1-synuclein as a biomarker for neurodegenerative disorders. The incorporation of a biomarker group [N\/\u03b1S] could contribute to provide better understanding and diagnosis of neurodegenerative disorders.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13195-020-00648-9","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T13:04:00Z","timestamp":1594645440000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["CSF total tau\/\u03b1-synuclein ratio improved the diagnostic performance for Alzheimer\u2019s disease as an indicator of tau phosphorylation"],"prefix":"10.1186","volume":"12","author":[{"given":"Kyu Hwan","family":"Shim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Ju","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Won","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Min","family":"Pyun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayoung","family":"Ryoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Ho","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Chul","family":"Youn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Won","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Hyang","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Hye","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoungho","family":"Suk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan-Woo","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan-Nyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Sung","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Soo A.","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SangYun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Alzheimer\u2019s Disease All Markers (ADAM) Research group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,13]]},"reference":[{"issue":"9533","key":"648_CR1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","volume":"368","author":"K Blennow","year":"2006","unstructured":"Blennow K, de Leon MJ, Zetterberg H. Alzheimer\u2019s disease. Lancet. 2006;368(9533):387\u2013403.","journal-title":"Lancet"},{"issue":"9770","key":"648_CR2","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0140-6736(10)61349-9","volume":"377","author":"C Ballard","year":"2011","unstructured":"Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer\u2019s disease. Lancet. 2011;377(9770):1019\u201331.","journal-title":"Lancet"},{"issue":"9503","key":"648_CR3","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/S0140-6736(05)67889-0","volume":"366","author":"CP Ferri","year":"2005","unstructured":"Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):2112\u20137.","journal-title":"Lancet"},{"issue":"6645","key":"648_CR4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839\u201340.","journal-title":"Nature."},{"issue":"10","key":"648_CR5","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1440-1827.1993.tb03230.x","volume":"43","author":"T Fukuda","year":"1993","unstructured":"Fukuda T, Tanaka J, Watabe K, Numoto RT, Minamitani M. Immunohistochemistry of neuronal inclusions in the cerebral cortex and brain-stem in Lewy body disease. Acta Pathologica Japonica. 1993;43(10):545\u201351.","journal-title":"Acta Pathologica Japonica"},{"issue":"2","key":"648_CR6","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1212\/WNL.51.2.351","volume":"51","author":"JM Olichney","year":"1998","unstructured":"Olichney JM, Galasko D, Salmon DP, Hofstetter CR, Hansen LA, Katzman R, et al. Cognitive decline is faster in Lewy body variant than in Alzheimer\u2019s disease. Neurology. 1998;51(2):351\u20137.","journal-title":"Neurology."},{"issue":"3","key":"648_CR7","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1750-3639.2000.tb00269.x","volume":"10","author":"RL Hamilton","year":"2000","unstructured":"Hamilton RL. Lewy bodies in Alzheimer\u2019s disease: a neuropathological review of 145 cases using \u03b1-synuclein immunohistochemistry. Brain Pathol. 2000;10(3):378\u201384.","journal-title":"Brain Pathol"},{"issue":"2","key":"648_CR8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0006-8993(00)03082-1","volume":"888","author":"Y Arai","year":"2001","unstructured":"Arai Y, Yamazaki M, Mori O, Muramatsu H, Asano G, Katayama Y. \u03b1-Synuclein-positive structures in cases with sporadic Alzheimer\u2019s disease: morphology and its relationship to tau aggregation. Brain Res. 2001;888(2):287\u201396.","journal-title":"Brain Res"},{"issue":"4","key":"648_CR9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/jnen\/62.4.363","volume":"62","author":"L Parkkinen","year":"2003","unstructured":"Parkkinen L, Soininen H, Alafuzoff I. Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease. J Neuropathol Exp Neurol. 2003;62(4):363\u20137.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"21","key":"648_CR10","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","volume":"30","author":"LK Clinton","year":"2010","unstructured":"Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic interactions between A\u03b2, tau, and \u03b1-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci. 2010;30(21):7281\u20139.","journal-title":"J Neurosci"},{"issue":"30","key":"648_CR11","doi-asserted-by":"crossref","first-page":"10253","DOI":"10.1523\/JNEUROSCI.0581-12.2012","volume":"32","author":"ME Larson","year":"2012","unstructured":"Larson ME, Sherman MA, Greimel S, Kuskowski M, Schneider JA, Bennett DA, et al. Soluble \u03b1-synuclein is a novel modulator of Alzheimer\u2019s disease pathophysiology. J Neurosci. 2012;32(30):10253\u201366.","journal-title":"J Neurosci"},{"issue":"9","key":"648_CR12","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.neurobiolaging.2006.06.013","volume":"28","author":"C Freichel","year":"2007","unstructured":"Freichel C, Neumann M, Ballard T, M\u00fcller V, Woolley M, Ozmen L, et al. Age-dependent cognitive decline and amygdala pathology in \u03b1-synuclein transgenic mice. Neurobiol Aging. 2007;28(9):1421\u201335.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"648_CR13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00401-012-0983-7","volume":"124","author":"JB Toledo","year":"2012","unstructured":"Toledo JB, Brettschneider J, Grossman M, Arnold SE, Hu WT, Xie SX, et al. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol. 2012;124(1):23\u201335.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"648_CR14","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00401-010-0654-5","volume":"119","author":"KA Jellinger","year":"2010","unstructured":"Jellinger KA, Attems J. Prevalence of dementia disorders in the oldest-old: an autopsy study. Acta Neuropathol. 2010;119(4):421\u201333.","journal-title":"Acta Neuropathol"},{"issue":"5","key":"648_CR15","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00401-011-0826-y","volume":"121","author":"PT Nelson","year":"2011","unstructured":"Nelson PT, Head E, Schmitt FA, Davis PR, Neltner JH, Jicha GA, et al. Alzheimer\u2019s disease is not \u201cbrain aging\u201d: neuropathological, genetic, and epidemiological human studies. Acta Neuropathol. 2011;121(5):571\u201387.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"648_CR16","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"648_CR17","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00401-013-1148-z","volume":"126","author":"JB Toledo","year":"2013","unstructured":"Toledo JB, Korff A, Shaw LM, Trojanowski JQ, Zhang J. CSF \u03b1-synuclein improves diagnostic and prognostic performance of CSF tau and A\u03b2 in Alzheimer\u2019s disease. Acta Neuropathol. 2013;126(5):683\u201397.","journal-title":"Acta Neuropathol"},{"issue":"5, Supplement","key":"648_CR18","doi-asserted-by":"crossref","first-page":"S290","DOI":"10.1016\/j.jalz.2013.10.004","volume":"10","author":"S Slaets","year":"2014","unstructured":"Slaets S, Vanmechelen E, Le Bastard N, Decraemer H, Vandijck M, Martin J-J, et al. Increased CSF \u03b1-synuclein levels in Alzheimer\u2019s disease: correlation with tau levels. Alzheimer's Dementia. 2014;10(5, Supplement):S290\u2013S8.","journal-title":"Alzheimer's Dementia"},{"key":"648_CR19","first-page":"40263","volume":"7","author":"NK Majbour","year":"2017","unstructured":"Majbour NK, Chiasserini D, Vaikath NN, Eusebi P, Tokuda T, van de Berg W, et al. Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable. Alzheimer\u2019s Disease. 2017;7:40263.","journal-title":"Alzheimer\u2019s Disease"},{"issue":"12","key":"648_CR20","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.jalz.2018.06.3053","volume":"14","author":"A Vergallo","year":"2018","unstructured":"Vergallo A, Bun R-S, Toschi N, Baldacci F, Zetterberg H, Blennow K, et al. Association of cerebrospinal fluid \u03b1-synuclein with total and phospho-tau181 protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer\u2019s disease biomarkers. Alzheimers Dement. 2018;14(12):1623\u201331.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"648_CR21","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1474-4422(11)70014-X","volume":"10","author":"B Mollenhauer","year":"2011","unstructured":"Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG. Alpha-synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011;10(3):230\u201340.","journal-title":"Lancet Neurol"},{"issue":"11","key":"648_CR22","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archneurol.2012.1654","volume":"69","author":"S Hall","year":"2012","unstructured":"Hall S, \u00d6hrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and\/or parkinsonian disorders. Arch Neurol. 2012;69(11):1445\u201352.","journal-title":"Arch Neurol"},{"issue":"4","key":"648_CR23","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3233\/JAD-130458","volume":"36","author":"A Korff","year":"2013","unstructured":"Korff A, Liu C, Ginghina C, Shi M, Zhang J. Alzheimer\u2019s disease neuroimaging I. \u03b1-Synuclein in cerebrospinal fluid of Alzheimer\u2019s disease and mild cognitive impairment. J Alzheimer's Dis. 2013;36(4):679\u201388.","journal-title":"J Alzheimer's Dis"},{"issue":"3","key":"648_CR24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/WAD.0b013e31823899cc","volume":"26","author":"F Tateno","year":"2012","unstructured":"Tateno F, Sakakibara R, Kawai T, Kishi M, Murano T. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis Assoc Disord. 2012;26(3):213\u20136.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"1","key":"648_CR25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053250","volume":"8","author":"M Wennstr\u00f6m","year":"2013","unstructured":"Wennstr\u00f6m M, Surova Y, Hall S, Nilsson C, Minthon L, Bostr\u00f6m F, et al. Low CSF levels of both \u03b1-synuclein and the \u03b1-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS One. 2013;8(1):e53250.","journal-title":"PLoS One"},{"issue":"1","key":"648_CR26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13024-019-0320-x","volume":"14","author":"D Twohig","year":"2019","unstructured":"Twohig D, Nielsen HM. Alpha-synuclein in the pathophysiology of Alzheimer\u2019s disease. Mol Neurodegener. 2019;14(1):23.","journal-title":"Mol Neurodegener"},{"issue":"10","key":"648_CR27","first-page":"1277","volume":"70","author":"J Kang","year":"2013","unstructured":"Kang J, Irwin DJ, Chen-Plotkin AS, et al. Association of cerebrospinal fluid \u03b2-amyloid 1-42, t-tau, p-tau181, and \u03b1-synuclein levels with clinical features of drug-naive patients with early parkinson disease. JAMA Neurol. 2013;70(10):1277\u201387.","journal-title":"JAMA Neurol"},{"issue":"1","key":"648_CR28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s40478-018-0624-z","volume":"6","author":"D Twohig","year":"2018","unstructured":"Twohig D, Rodriguez-Vieitez E, Sando SB, Berge G, Lauridsen C, M\u00f8ller I, et al. The relevance of cerebrospinal fluid \u03b1-synuclein levels to sporadic and familial Alzheimer\u2019s disease. Acta Neuropathologica Communications. 2018;6(1):130.","journal-title":"Acta Neuropathologica Communications"},{"issue":"1","key":"648_CR29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1750-1326-9-43","volume":"9","author":"S Moussaud","year":"2014","unstructured":"Moussaud S, Jones DR, Moussaud-Lamodi\u00e8re EL, Delenclos M, Ross OA, McLean PJ. Alpha-synuclein and tau: teammates in neurodegeneration? Mol Neurodegener. 2014;9(1):43.","journal-title":"Mol Neurodegener"},{"issue":"36","key":"648_CR30","doi-asserted-by":"crossref","first-page":"25481","DOI":"10.1074\/jbc.274.36.25481","volume":"274","author":"PH Jensen","year":"1999","unstructured":"Jensen PH, Hager H, Nielsen MS, H\u00f8jrup P, Gliemann J, Jakes R. \u03b1-Synuclein binds to tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J Biol Chem. 1999;274(36):25481\u20139.","journal-title":"J Biol Chem"},{"issue":"3","key":"648_CR31","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1074\/jbc.M102981200","volume":"277","author":"MA Alim","year":"2002","unstructured":"Alim MA, Hossain MS, Arima K, Takeda K, Izumiyama Y, Nakamura M, et al. Tubulin seeds \u03b1-synuclein fibril formation. J Biol Chem. 2002;277(3):2112\u20137.","journal-title":"J Biol Chem"},{"issue":"4","key":"648_CR32","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3233\/JAD-2004-6412","volume":"6","author":"MA Alim","year":"2004","unstructured":"Alim MA, Ma QL, Takeda K, Aizawa T, Matsubara M, Nakamura M, et al. Demonstration of a role for alpha-synuclein as a functional microtubule-associated protein. J Alzheimer's Dis. 2004;6(4):435\u201342 discussion 43-9.","journal-title":"J Alzheimer's Dis"},{"issue":"24","key":"648_CR33","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1111\/j.1742-4658.2011.08389.x","volume":"278","author":"F Kawakami","year":"2011","unstructured":"Kawakami F, Suzuki M, Shimada N, Kagiya G, Ohta E, Tamura K, et al. Stimulatory effect of \u03b1-synuclein on the tau-phosphorylation by GSK-3\u03b2. FEBS J. 2011;278(24):4895\u2013904.","journal-title":"FEBS J"},{"issue":"9","key":"648_CR34","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med. 2012;367(9):795\u2013804.","journal-title":"N Engl J Med"},{"issue":"8","key":"648_CR35","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.jalz.2018.02.015","volume":"14","author":"M Shi","year":"2018","unstructured":"Shi M, Tang L, Toledo JB, Ginghina C, Wang H, Aro P, et al. Cerebrospinal fluid \u03b1-synuclein contributes to the differential diagnosis of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(8):1052\u201362.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"648_CR36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr","year":"2013","unstructured":"Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207\u201316.","journal-title":"Lancet Neurol"},{"issue":"2","key":"648_CR37","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3233\/JAD-160722","volume":"55","author":"P Lewczuk","year":"2017","unstructured":"Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P, et al. Cerebrospinal fluid A\u03b242\/40 corresponds better than A\u03b242 to amyloid PET in Alzheimer\u2019s disease. J Alzheimer\u2019s Dis. 2017;55(2):813\u201322.","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"2","key":"648_CR38","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3233\/JAD-170327","volume":"60","author":"E Niemantsverdriet","year":"2017","unstructured":"Niemantsverdriet E, Ottoy J, Somers C, De Roeck E, Struyfs H, Soetewey F, et al. The cerebrospinal fluid Abeta1-42\/Abeta1-40 ratio improves concordance with amyloid-PET for diagnosing Alzheimer\u2019s disease in a clinical setting. J Alzheimer\u2019s Dis. 2017;60(2):561\u201376.","journal-title":"J Alzheimer\u2019s Dis"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00648-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-020-00648-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00648-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T00:02:21Z","timestamp":1723248141000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-020-00648-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,13]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["648"],"URL":"https:\/\/doi.org\/10.1186\/s13195-020-00648-9","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,13]]},"assertion":[{"value":"26 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the ethics committee of all participating institutions, and all participants gave informed consent to the use of clinical data for research purposes.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"83"}}